

June 06, 2023

Cropnosys India Pvt Ltd: Ratings upgraded; rated amount enhanced

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long term Fund Based Cash Credit	45.00	45.00	[ICRA]A-(Stable); upgraded from [ICRA]BBB+(Stable)
Long term/short term- Fund based/ non fund based-Others	0.00	25.00	[ICRA]A-(Stable)/A2+; upgraded from [ICRA]BBB+(Stable)/[ICRA]A2; assigned for enhanced amount
Long term/short term - Unallocated limits	5.00	0.00	-
Total	50.00	70.00	

*Instrument details are provided in Annexure-I

Rationale

The rating upgrade factors in the improved financial profile of Cropnosys India Pvt Ltd (CIPL) with significant revenue growth and better margins and coverage metrics in FY2023. The operating income increased by 47% to Rs. 675 crore in FY2023 from Rs. 460 crore in FY2022, supported by healthy volume growth owing to new registrations received for existing products in a new geography i.e Brazil. The operating margins have remained healthy over the last few years and further improved in FY2023 owing to the increased scale that resulted in better absorption of fixed costs, and reduced dependence on job work with the commissioning of the new capacity in December 2022. The operating margins are expected to remain healthy, going forward, with the increasing scale of operations and reduced dependence on job work for manufacturing.

The coverage indicators remained strong with interest coverage at 47 times and NCA/TD at 216% in FY2023 owing to the healthy margins and low debt levels. The ratings also factor in the extensive experience of the promoters of over two decades in the agrochemical industry. Further, the company caters to a diversified customer base across the international and domestic markets. The company's exports are geographically diversified across Europe, the Asia Pacific and Australia and New Zealand and the domestic sales are spread across 11 states.

The ratings are, however, constrained by product concentration risk as three major products have been contributing to majority of the revenues in the last few years. The contribution of the three products was 74% of the total revenue in 9M FY2023 vis-à-vis 60% in FY2022. However, the major active ingredients (Ais) produced by CIPL are used to manufacture diverse formulations. Further, the company has been increasing its registrations over the years and expects to add many molecules to the AI portfolio, going forward.

The ratings are also constrained by the high working capital-intensive operations on account of the high debtors and inventory levels. Given the seasonality of the business, the receivables have significantly increased in the last few months of the financial year, impacting the working capital cycle. The ratings further remain exposed to raw material procurement and price risks as some portion of the raw materials is still procured from China. However, the company has reduced its dependence on China by procuring from domestic suppliers in the last few years. The company remains exposed to foreign exchange volatility due to the significant export revenues. However, imports act as a natural hedge to an extent. Further, the agrochemical industry is highly regulated in both the international and domestic markets and the industry is susceptible to agro-climatic risks.

The Stable outlook on the [ICRA]A- rating reflects ICRA's opinion that CIPL will continue to benefit from the vast experience of its promoters, its established track record over the years and a strong financial profile with increasing revenues, healthy profitability and coverage metrics.

Key rating drivers and their description

Credit strengths

Significant revenue growth with improved margins and coverage metrics - The operating income increased by 47% to Rs. 675 crore in FY2023 from Rs. 460 crore in FY2022, supported by healthy volume growth owing to new registrations received for existing products in a new geography i.e Brazil. The operating margins have remained healthy over the last few years and further improved in FY2023 owing to the increased scale, resulting in better absorption of fixed costs. The operating margins were also supported by the commissioning of the increased capacity in December 2022, reducing the dependence on job work. The operating margins are expected to remain healthy, going forward, with the increased scale of operations and reduced dependence on job work for manufacturing. The coverage indicators remained healthy with interest coverage at 47 times and NCA/TD at 216% in FY2023 owing to the healthy margins and low debt levels.

Extensive experience of promoters in agrochemical industry - CIPL is promoted by Mr. Gurvinder Singh in 2006. He is also the founder of UK-based Widecover Ltd and has about 25 years' experience in the agrochemical industry. Widecover is engaged in the trading of active ingredients, intermediates and formulations. Further, the Group also manufactures formulations under the entity - Cropthetics, UK.

Diversified customer base with track record of repeat business - The company caters to a diversified customer base across the international and domestic markets. The company's exports are geographically diversified across Europe, Asia Pacific, Japan, Australia and New Zealand. Further, the company's domestic sales are spread across 10-11 states. The company has been receiving repeat orders from its existing customers.

Credit challenges

Product concentration risk - CIPL faces product concentration risk compared to the other industry players involved in the agrochemical industry who have a diverse product portfolio. CIPL manufactures intermediates and AIs, mostly in the herbicide and fungicide categories. The three major AIs produced by CIPL are FFC (Fluazinam Technical, herbicide), FATM (Flufenacet Technical, fungicide) and DTH (Dithianon) which contributed to almost 60% of the total revenue in FY2022 and ~74% in 9M FY2023. However, the major AIs produced by CIPL are used to manufacture diverse formulations. Further, the company has been increasing its registrations over the years and expects to add many molecules to the AI portfolio, going forward.

Raw material procurement and price risks and foreign exchange volatility - About 40-50% of CIPL's total raw material requirement was earlier met through imports, majorly from Chinese suppliers, exposing the company to concentration risk. Any significant disruption in supply from China could have had an adverse impact on the company's operations and profit margins. However, the company has been reducing the concentration from China by procuring from domestic suppliers. The company is also exposed to foreign exchange volatility due to the significant export revenues.

Regulated nature of industry and agro-climatic risk - The agrochemical industry is highly regulated in both the international and domestic markets. Further, any new product takes 3-5 years for getting registered. Poor monsoons translate into slower agrochemical offtake and, therefore, affect the performance of the agrochemical entities. However, the risk for CIPL is mitigated, to some extent, by its diversified geographical presence across countries internationally and across states in the domestic market.

High working capital intensity - The working capital intensity remained high because of the high receivables and inventory levels. Given the seasonality of the business, the receivables have increased significantly since 2021, impacting the working capital cycle. Further, the company is required to maintain high finished goods inventory at the beginning of the seasons. It also has to maintain a high level of raw material inventory as a significant portion is met through imports. CIPL gives a credit period of about 90-120 days to its customers. The nature of the business is export-oriented and considering the industry and sales in various geographies, the debtor days are likely to remain high. The NWC/OI stood at 35% as on March 31, 2023 and is likely to remain at similar levels in the future.

Liquidity position: Adequate

CIPL's liquidity is adequate with expected healthy cash flow from operations in FY2024, cash and bank balances of ~Rs. 30 crore and undrawn working capital limits of ~Rs. 23 crore as on March 31, 2023. It has utilised bank limits of 62% on an average in the last few months. CIPL is expected to seek an enhancement in the bank lines, which would support the working capital requirements for the expected revenue growth, going forward. CIPL has a debt repayment of Rs. 7.40 crore in FY2024 and a capex commitment of ~Rs. 60 crore in FY2024 out of the proposed capex of around Rs. 200 crore over the next three years to set up a new unit, which is likely to be funded from internal accruals.

Rating sensitivities

Positive factors – The rating could be upgraded if the company is able to significantly scale up its revenue and profitability on a sustained basis along with diversifying its product profile and maintaining its liquidity position.

Negative factors – Pressure on CIPL's ratings could arise if the revenues and operating margins decline, resulting in lower cash flows on a sustained basis. Deterioration in the working capital cycle and any sizeable debt-funded capex impacting the company's liquidity position could also be a trigger for a downgrade. The rating may also be downgraded if the TOL/TNW is greater than 1.2 times on a sustained basis.

Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Rating Methodology for entities in Agrochemicals Industry
Parent/Group support	Not Applicable
Consolidation/Standalone	Standalone

About the company:

Cropnosys India Private Limited (CIPL) was started in April 2006 by Mr. Gurvinder Singh. It is currently involved in the manufacturing of crop protection products across categories such as herbicides, fungicides, insecticides, etc. The company is also involved in the sales of crop micronutrient products. The company has two manufacturing facilities at Vapi with an installed annual capacity of 2,400 MT per annum.

Key financial indicators (audited)

Standalone	FY2021	FY2022	FY2023*
Operating income	308.0	459.3	675.8
PAT	41.9	67.0	113.6
OPBDIT/OI	17.9%	18.4%	21.1%
PAT/OI	13.6%	14.6%	16.8%
Total outside liabilities/Tangible net worth (times)	1.0	1.3	1.0
Total debt/OPBDIT (times)	0.3	0.6	0.4
Interest coverage (times)	53.3	39.9	47.0

PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation; Amount in Rs crore*Provisional

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Type	Current rating (FY2024)		Chronology of rating history for the past 3 years			
		Amount rated (Rs. crore)	Amount outstanding as on Mar 31, 2023 (Rs. crore)	Date & rating in FY2024	Date & rating in FY2023	Date & rating in FY2022	Date & rating in FY2021
				June 06, 2023	May 04, 2022		
1 Cash credit	Long term	45.0	-	[ICRA]A-(Stable)	[ICRA]BBB+ (Stable)	-	-
2 Fund based/non fund based - Others	Long term and short term	25.0	-	[ICRA]A-(Stable)/ [ICRA]A2+	-	-	-
3 Unallocated	Long term and short term	0.0	-	-	[ICRA]BBB+ (Stable)/[ICRA]A2	-	-

Complexity level of the rated instruments

Instrument	Complexity Indicator
Long-term fund-based – Cash credit	Simple
Long term/short term- Fund based/ non fund based - Others	Simple
Long-term/Short-term – Unallocated limits	Not applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure I: Instrument details

ISIN	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Cash credit	NA	NA	NA	45.00	[ICRA]A-(Stable)
NA	Fund based/non fund based - Others	NA	NA	NA	25.00	[ICRA]A-(Stable)/ [ICRA]A2+

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis- Not applicable

ANALYST CONTACTS

Sabyasachi Majumdar

+91 12 4454 5304

sabyasachi@icraindia.com

Prashant Vashist

+91 12 4454 5322

prashant.vasisht@icraindia.com

Kushal Kumar

+91 40 4547 4829

kushal.kumar@icraindia.com

Deep Shaliesh Vakil

+91 022 6169 3352

deep.vakil@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2023 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.